<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089738</url>
  </required_header>
  <id_info>
    <org_study_id>B1651003</org_study_id>
    <nct_id>NCT01089738</nct_id>
  </id_info>
  <brief_title>A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals</brief_title>
  <official_title>An Investigator And Subject-Blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of PF-03382792 In Healthy Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to look at the safety and blood concentrations of PF-03382792 in
      healthy elderly subjects after taking multiple doses for 14 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To examine safety, toleratibilty and pharmacokinetics of PF-03382792 in healthy elderly
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Endpoints include: AEs, vital signs, triplicate ECGs,</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Endpoints include: Cosyntropin Stimulation Test, Clinical Examinations, Slit Lamp Examination, Aldosterone Concentrations</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Endpoints include: safety laboratory endpoints (including a complete blood count and a full chemistry panel, including electrolytes, hepatic transaminases, and urinalysis, with microscopic analysis if dipstick analysis is positive),</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic endpoints include: Plasma concentrations of PF 03382792 and its N dealkylated metabolite, PF 03227077, will be measured and used to determine Cmax, Tmax, AUC on Day 1 and Css,max, Tss,max, AUC, Css,min, Css,avg on Days 7 and 14.</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Additional pharmacokinetic endpoints: the accumulation ratio (Rac) will be determined from Day 14 and Day 1 AUC. If data permit, t1/2 and urinary excretion parameters (CLR for the parent and Ae and Ae%) will be calculated.</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>No secondary outcomes</measure>
    <time_frame>No secondary outcomes</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending Doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03382792 0.5mg</intervention_name>
    <description>0.5 mg PF-03382792, qd, for 14 days or placebo</description>
    <arm_group_label>Dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03382792 1.5 mg</intervention_name>
    <description>1.5 mg PF-03382792, qd, for 14 days or placebo</description>
    <arm_group_label>Dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03382792 5 mg</intervention_name>
    <description>5 mg PF-03382792, qd, for 14 days or placebo</description>
    <arm_group_label>Dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03382792 15 mg</intervention_name>
    <description>15 mg PF-03382792, qd, for 14 days or placebo</description>
    <arm_group_label>Dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteer aged 65-80 years old

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2

          -  Total body weight &gt;50 kg (110 lbs).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Subjects with symptoms or signs of adrenal insufficiency.

          -  Subjects with clinically significant ocular lens abnormalities as detected by the
             investigator based on the findings of a slit lamp examination performed by an
             ophthalmologist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1651003&amp;StudyName=A%20Study%20To%20Look%20At%20Safety%20And%20Blood%20Concentrations%20After%20Multiple%20Doses%20Of%20PF-03382792%20In%20Healthy%20Elderly%20Individuals%0A</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>mulitple dose</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>healthy elderly volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

